Verition Fund Management
MRTX

Verition Fund Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Verition Fund Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-46,599
Closed -$2.74M – 3053
2023
Q4 		$2.74M Sell
46,599
-159,880
-77% -$8.99M 0.02% 691
2023
Q3 		$8.99M Buy
206,479
+198,801
+2,589% +$7.1M 0.1% 250
2023
Q2 		$277K Sell
7,678
-3,978
-34% -$164K ﹤0.01% 1616
2023
Q1 		$433K Buy
11,656
+6,145
+112% +$276K 0.01% 1323
2022
Q4 		$250K Sell
5,511
-162
-3% -$10.5K ﹤0.01% 1609
2022
Q3 		$396K Hold
5,673
– – ﹤0.01% 2047
2022
Q2 		$381K Buy
+5,673
New +$361K 0.01% 1598
2022
Q1 		– Sell
-32,027
Closed -$4.7M – 3130
2021
Q4 		$4.7M Buy
32,027
+9,231
+40% +$1.43M 0.03% 393
2021
Q3 		$4.03M Buy
22,796
+19,631
+620% +$3.16M 0.03% 342
2021
Q2 		$511K Buy
+3,165
New +$508K ﹤0.01% 1082
2018
Q2 		– Sell
-9,141
Closed -$281K – 1391
2018
Q1 		$281K Buy
+9,141
New +$254K 0.02% 858

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Verition Fund Management's MRTX Position: Q1 2024 in Review

Verition Fund Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 46,599 shares — an estimated $2.74M sold.

Verition Fund Management first reported a position in MRTX in Q1 2018 and held it in 11 quarters. The position peaked at $8.99M in Q3 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Verition Fund Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Verition Fund Management sold 46,599 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.74M.
  • Verition Fund Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 11 quarters.
  • Verition Fund Management's Mirati Therapeutics, Inc. Common Stock position peaked at $8.99M in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Verition Fund Management's 13F filing for Q1 2024, filed 14 May 2024.